Business
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate receptor-bound IgE and drive faster, deeper pathway suppression - Exl-111 would complement existing Novartis portfolio in allergy with potential to improve both symptom control and convenience Basel, March 27, 2026 – Novartis today announced that it has entered into an agreement to ac
About this update from Novartis Ag
[{"type":"image","alt":"Novartis Pharma AG","displaySize":"","headline":null,"caption":"Novartis Pharma AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":104,"url":"https://media.zenfs.com/en/globenewswire.com/3c597efe92519a4a8a646c2639fa7252"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/x1Rza7IeLy1J5DmWciMF8A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Ng--/https://media.zenfs.com/en/globenewswire.com/3c597efe92519a4a8a646c2639fa7252","width":300,"height":104}},"lazy":false},{"type":"text","content":"- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate receptor-bound IgE and drive faster, deeper pathway suppression - Exl-111 would complement existing Novartis portfolio in allergy with potential to improve both symptom control and convenience Basel, March 27, 2026 – Novartis today announced that it has entered into an agreement to acquire Excellergy, Inc., a private biotech company developing next-generation anti-IgE therapies for IgE-driven diseases. The proposed acquisition adds Exl-111, a half-life extended, high-affinity anti-IgE antibody in Phase 1. The acquisition builds on deep Novartis expertise in IgE biology and a long-standing presence in allergic disease. Exl-111 is designed as a next-generation extension of validated biology established by anti-IgE therapy, with the potential to complement the Novartis existing allergy portfolio across a range of allergic conditions and patient settings. “Excellergy adds a differentiated next-generation anti-IgE program that builds on biology Novartis knows well, supported by preclinical evidence and early clinical pharmacokinetic data,” said Fiona Marshall, President of Biomedical Research at Novartis. “Exl-111 is designed to go beyond conventional anti-IgE therapy, with the potential to deliver faster and deeper suppression of IgE signaling as well as improved symptom control. This proposed acquisition strengthens our allergy portfolio and reflects our strategy of advancing innovative bold science to bring meaningful additional benefits to patients.” IgE is a central driver of multiple allergic diseases. Unlike conventional anti-I...